

**ACTION:** Notice of application.

**SUMMARY:** S&B Pharma LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 26, 2022. Such persons may also file a written request for a hearing on the application on or before April 26, 2022.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on December 24, 2021, S&B Pharma LLC, 405 South Motor Avenue, Azusa, California 91702, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid.	2010	I
Marihuana .....	7360	I
Tetrahydrocannabinols	7370	I
Amphetamine .....	1100	II
Methamphetamine .....	1105	II
Lisdexamfetamine .....	1205	II
Methylphenidate .....	1724	II
Pentobarbital .....	2270	II
4-Anilino-N-Phenethyl-4-Piperidine (ANPP).	8333	II
Tapentadol .....	9780	II
Fentanyl .....	9801	II

The company plans to bulk manufacture the listed controlled substances for the internal use intermediates for formulation and analytical development purposes or for sale to its customers. In reference to drug codes 7360 (Marihuana), and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetic. No other activities for these drug codes are authorized for this registration.

**Matthew J. Strait,**  
Deputy Assistant Administrator.  
[FR Doc. 2022-04062 Filed 2-24-22; 8:45 am]  
**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-974]

**Bulk Manufacturer of Controlled Substances Application: Cedarburg Pharmaceuticals**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Cedarburg Pharmaceuticals has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 26, 2022. Such persons may also file a written request for a hearing on the application on or before April 26, 2022.

**ADDRESSES:** DEA requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <http://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <http://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment."

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on August 27, 2021, Cedarburg Pharmaceuticals, 870 Badger Circle, Grafton, Wisconsin 53024-0000, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Lysergic Acid Diethylamide.	7315	I
Tetrahydrocannabinols	7370	I
4-Bromo-2,5-Dimethoxyphenethylamine.	7392	I
3,4-Methylenedicyamphetamine.	7400	I

Controlled substance	Drug code	Schedule
3,4-Methylenedioxyamphetamine.	7405	I
5-Methoxy-N,N-dimethyltryptamine.	7431	I
Dimethyltryptamine .....	7435	I
Psilocybin .....	7437	I
Psilocyn .....	7438	I
Methylphenidate .....	1724	II
Nabilone .....	7379	II
4-Anilino-N-Phenethyl-4-Piperidine (ANPP).	8333	II
Fentanyl .....	9801	II

The company plans to bulk manufacture the listed controlled substances for the internal use intermediates or for sale to its customers. In reference to the drug code 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture as synthetic. No other activity for this drug code is authorized for this registration.

**Matthew J. Strait,**  
Deputy Assistant Administrator.  
[FR Doc. 2022-04064 Filed 2-24-22; 8:45 am]  
**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-964]

**Bulk Manufacturer of Controlled Substances Application: Synthcon LLC**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Synthcon LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTAL INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 26, 2022. Such persons may also file a written request for a hearing on the application on or before April 26, 2022.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on December 2, 2021,

Synthcon LLC, 770 Wooten Road, Suite 101, Colorado Springs, Colorado 80915-3538, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
3-FMC	1233	I
Cathinone	1235	I
Methcathinone	1237	I
4-FMC	1238	I
Pentedrone	1246	I
Mephedrone(4-Methyl-N-methylcathinone)	1248	I
4-MEC	1249	I
Naphyrone	1258	I
N-Ethylamphetamine	1475	I
N,N-Dimethylamphetamine	1480	I
Aminorex	1585	I
Cis-4-Methylaminorex	1590	I
GHB	2010	I
Methaqualone	2565	I
Mecloqualone	2572	I
JWH-250	6250	I
ADB-PINACA	7035	I
JWH-018	7118	I
JWH-073	7173	I
JWH-200	7200	I
JWH-203	7203	I
4-Methyl-alpha-ethylaminopentiophenone	7245	I
N-Ethyhexedrone	7246	I
AET	7249	I
Ibogaine	7260	I
CP-47,497	7297	I
CP-47,497 C8 HOMOLOG	7298	I
LSD	7315	I
2C-T-7	7348	I
Tetrahydrocannabinols	7370	I
Mescaline	7381	I
2C-T-2	7385	I
3,4,5-TMA	7390	I
DOB	7391	I
2CB	7392	I
DOM	7395	I
2,5-DMA	7396	I
JWH-398	7398	I
DOE	7399	I
MDA	7400	I
5-METHOXY-MDA	7401	I
N-HYDROXY-MDA	7402	I
MDEA	7404	I
MDMA	7405	I
PMA	7411	I
5-MeO-DMT	7431	I
AMT	7432	I
Bufotenine	7433	I
DET	7434	I
DMT	7435	I
Psilocybin	7437	I
Psilocin	7438	I
5-Methoxy-N,N-diisopropyltryptamine	7439	I
4-Methyl-alpha-pyrrolidinohexiophenone	7446	I
PCE	7455	I
PCPy	7458	I
TCP	7470	I
TCPy	7473	I
JB323	7482	I
JB336	7484	I
BZP	7493	I
4-MePPP	7498	I
2C-D	7508	I
2C-E	7509	I
2C-H	7517	I
2C-I	7518	I
2C-C	7519	I
2C-N	7521	I
2C-P	7524	I
2C-T-4	7532	I

Controlled substance	Drug code	Schedule
MDPV .....	7535	I
25B-NBOME .....	7536	I
25C-NBOME .....	7537	I
25I-NBOME .....	7538	I
Methylone .....	7540	I
Butylone .....	7541	I
Pentylone .....	7542	I
N-Ethylpentylone .....	7543	I
Alpha-Pyrrolidinohexanophenone .....	7544	I
Alpha-PVP .....	7545	I
Alpha-PBP .....	7546	I
Ethylone .....	7547	I
AM-694 .....	7694	I
Etorphine .....	9056	I
Heroin .....	9200	I
Normorphine .....	9313	I
Acetorphine .....	9319	I
U-47700 .....	9547	I
AH-7921 .....	9551	I
MT-45 .....	9560	I
Acetylmethadol .....	9601	I
Allylprodine .....	9602	I
Alphacetylmethadol .....	9603	I
Alphameprodine .....	9604	I
Alphamethadol .....	9605	I
Benzethidine .....	9606	I
Betacetylmethadol .....	9607	I
Clonitazene .....	9612	I
Isontonitazene .....	9614	I
Diampromide .....	9615	I
Diethylthiambutene .....	9616	I
Dimethylthiambutene .....	9619	I
Etonitazene .....	9624	I
Ketobemidone .....	9628	I
MPPP .....	9661	I
PEPAP .....	9663	I
Tilidine .....	9750	I
Acryl Fentanyl .....	9811	I
Para-fluorofentanyl .....	9812	I
3-Methylfentanyl .....	9813	I
Alpha-methylfentanyl .....	9814	I
Acetyl-alpha-methylfentanyl .....	9815	I
Ortho-fluorofentanyl .....	9816	I
Acetylfentanyl .....	9821	I
Butyrylfentanyl .....	9822	I
Para-fluorofentanyl .....	9823	I
4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide) .....	9824	I
Methoxyacetyl fentanyl .....	9825	I
Para-chloroisobutyryl fentanyl .....	9826	I
Isobutyrylfentanyl .....	9827	I
Beta-Hydroxyfentanyl .....	9830	I
Beta-Hydroxy-3-methylfentanyl .....	9831	I
Alpha-Methylthiofentanyl .....	9832	I
3-Methylthiofentanyl .....	9833	I
Furanylfentanyl .....	9834	I
Thiofentanyl .....	9835	I
Beta-Hydroxythiofentanyl .....	9836	I
Para-Methoxybutyryl Fetnanyl .....	9837	I
Ocfentanil .....	9838	I
Valeryl Fentanyl .....	9840	I
Tetrahydrofuryl Fentanyl .....	9843	I
Crotonyl Fentanyl .....	9844	I
Cyclopropyl Fentanyl .....	9845	I
Cyclopentyl Fentanyl .....	9847	I
Fentanyl Related Compounds .....	9850	I
Amphetamine .....	1100	II
Methamphetamine .....	1105	II
1-Phenylcyclohexylamine .....	7460	II
PCP .....	7471	II
ANPP .....	8333	II
Norfentanyl .....	8366	II
P2P .....	8501	II
PCC .....	8603	II
Alphaprodine .....	9010	II

Controlled substance	Drug code	Schedule
Anileridine .....	9020	II
Cocaine .....	9041	II
Diphenoxylate .....	9170	II
Ecgonine .....	9180	II
Levorphanol .....	9220	II
Meperidine .....	9230	II
Meperidine Intermediate-A .....	9232	II
Meperidine Intermediate-B .....	9233	II
Meperidine Intermediate-C .....	9234	II
Dextropropoxyphene .....	9273	II
Morphine .....	9300	II
Levo-alphaacetylmethadol .....	9648	II
Alfentanil .....	9737	II
Remifentanil .....	9739	II
Sufentanil .....	9740	II
Carfentanil .....	9743	II
Tapentadol .....	9780	II
Fentanyl .....	9801	II

The company plans to bulk manufacture the listed controlled substances as analytical materials, proficiency test materials, and academic research materials for distribution to its customers. No other activities for these drug codes are authorized for this registration.

**Matthew J. Strait,**  
*Deputy Assistant Administrator.*  
 [FR Doc. 2022-04057 Filed 2-24-22; 8:45 am]  
**BILLING CODE P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-965]

**Importer of Controlled Substances Application: Lyndra Therapeutics**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Lyndra Therapeutics has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTAL INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 28, 2022. Such persons may also file a written request for a hearing on the application on or before March 28, 2022.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must

be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on January 13, 2022, Lyndra Therapeutics, 65 Grove Street, Suite 301, Watertown, Massachusetts 02472, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Methadone .....	9250	II

The company plans to develop the formulation and process, and then manufacture the finished oral dosage form for use in preclinical and human clinical trials and analysis. No other activity for this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

**Matthew J. Strait,**  
*Deputy Assistant Administrator.*  
 [FR Doc. 2022-04061 Filed 2-24-22; 8:45 am]  
**BILLING CODE 4410-09-P**

**DEPARTMENT OF LABOR**

**Agency Information Collection Activities; Submission for OMB Review; Comment Request; Miner's Claim for Benefits and Employment History**

**ACTION:** Notice of availability; request for comments.

**SUMMARY:** The Department of Labor (DOL) is submitting this Office of Workers' Compensation Programs (OWCP)-sponsored information collection request (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). Public comments on the ICR are invited.

**DATES:** The OMB will consider all written comments that the agency receives on or before March 28, 2022.

**ADDRESSES:** Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to [www.reginfo.gov/public/do/PRAMain](http://www.reginfo.gov/public/do/PRAMain). Find this particular information collection by selecting "Currently under 30-day Review—Open for Public Comments" or by using the search function.

Comments are invited on: (1) Whether the collection of information is necessary for the proper performance of the functions of the Department, including whether the information will have practical utility; (2) if the information will be processed and used in a timely manner; (3) the accuracy of the agency's estimates of the burden and cost of the collection of information, including the validity of the methodology and assumptions used; (4) ways to enhance the quality, utility and clarity of the information collection; and